Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT)

• S. García-Cabezas ^[1] ; C. Bueno ^[1] ; E. Rivin ^[2] ; J. M. Roldán ^[1] ; A. Palacios-Eito ^[1]
  1. [1] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  2. [2] Gustave Roussy Cancer Campus, Francia
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 8 (August), 2015, págs. 668-672
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To assess the clinical results in terms of local control, toxicity, failure pattern and toxicity of SBRT in oligometastatic patients with inoperable lung metastases.

    Methods Forty-four patients were treated (53 metastases). Dose regimen: 5 × 12 Gy (66 %), 8 × 7.5 Gy (20.8 %) and 10 × 5 Gy (13.2 %). Response was assessed using PET/CT at 6 months after SBRT.

    Results Local control at 1 and 2 years was 86.7 %. Seventy-five percent of local failures had received a BED <105 Gy. After a median follow-up of 13.3 months, 25 % experienced distant progression. Overall survival at 1 and 2 years was 86.7 and 60.4 %, and cancer-specific survival was 95.3 and 75.2 %, respectively. Grade 2 toxicity was 6.8 %. There was no grade 3–4 toxicity.

    Conclusion SBRT is effective and safe. The main failure pattern is distant progression. The selection of patients with a high probability of remaining oligometastatic is crucial for the efficiency of SBRT, both clinically and in terms of resources.